Samarium ¹⁵³Sm lexidronam Other names: Samarium-153

Chemical formula: C₆H₁₂N₂Na₅O₁₂P₄Sm  Molecular mass: 586.021 g/mol  PubChem compound: 76962714

Therapeutic indications

Samarium ¹⁵³Sm lexidronam is indicated for:

Bone pain in osteoblastic skeletal metastases

Population group: only adults (18 years old or older)

Samarium ¹⁵³Sm lexidronam is indicated for the relief of bone pain in patients with multiple painful osteoblastic skeletal metastases which take up technetium (99mTc)-labelled biphosphonates on bone scan.

The presence of osteoblastic metastases which take up technetium (99mTc)-labelled biphosphonates should be confirmed prior to therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Samarium ¹⁵³Sm lexidronam is contraindicated in the following cases:

Pregnancy

Pregnancy

Chemotherapy, radiation therapy

at least one of
Administration of antineoplastic agent
Antineoplastic agents
† Radiation oncology AND/OR radiotherapy

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2015: QUADRAMET Solution for injection
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈